Von: Richard L. Lindstrom, MD rllindstrom@mneye.comBetreff: FW: CV WorkDatum: 8. September 2015 15:18

An: Knorz@eyes.de

Hi#Michael:#I#would#like#to#nominate#Vance#Thompson#MD#for#membership#in#IIIC.#Vance#is#ainnovator#in#implants#and#has#par?cipated#in#numerous#clinical#trials.#He#teaches#both#in#the#USAand#abroad.#He#rarely#published#in#the#peer#reviewed#literature,#but#he#is#widely#quoted#in#theophthalmology#newspapers.#He#is#also#a#great#man#and#would#be#an#ac?ve#member.#I#believe#SteveArshinoff#will#also#recommend#him.#His#C.V.#is#aHached.#Warm#Regards:#Dick#L.#From: Vance Thompson [mailto:vance.thompson@vancethompsonvision.com] Sent: Monday, September 07, 2015 10:29 AMTo: Richard L. Lindstrom, MD; Steve Arshinoff, MD FRCSCSubject: Fwd: CV Work

Dear Dick and Steve, I have worked on updating my CV for your consideration to the International Intra-OcularImplant Club. I have not been the best at updating this over the years. I work hard and don't dothe best job of documenting it via CV. As you can see from my CV if there is a central theme itis hard work in FDA monitored studies. I was the largest implanter in the Artisan United StatesFDA monitored trial and was the investigator chosen to represent that technology at the FDAhearing. According to Abbott I continue to be their US Verisyse user with the largestexperience.I was the largest AcuFocus implanter in the early phases and ended up the 2ndlargest implanter in that trial overall and asked to represent this technology at the FDA trial.Phakic IOL's and inlays are areas where I have been a leader in the research arena for theUnited States. You both know I have also been a leader in femtosecond laser (cornea and lens)research from the beginning. I also was there at the beginning of intraoperative aberrometry. Iguess I could go on but I think I will let the rest speak for itself to see if this qualifies for yourprestigious club. I would be so honored to be a part of it. Since you both have expressed an interest in my and since I have an immense amount ofrespect for you both I chose to send this to you both. Sincerely,Your friend and comrade,Vance

The PHI (Protected Health Information) and other information contained in this email is HIGHLY CONFIDENTIAL. All information in this email is intendedfor the exclusive use of the addressee. If you have received this communication in error you should immediately delete it. Patient information is to beused only to aid in providing healthcare services to this patient. Any other use is a violation of Federal Law (HIPAA) and will be reported as such.Patients using email as a form of communication with physicians should be aware that not all email traffic is secure.

Vance Thompson CV2015.pdf

Von: SAMD ifix2is@gmail.comBetreff: Re: CV WorkDatum: 30. September 2015 22:59

An: Michael C. Knorz knorz@eyes.de

Hi Michael,I have known Vance Thompson for over 20 years.He is a real gentleman, a very hard worker, and an innovator.He has been involved both in keratorefractive and implants, and I am sure will be an active interested member of the club.He has been active mostly in the USA, but I believe he is known globally.He has been under published in the peer-reviewed literature, and this may be a concern of other members, limiting his global reach. He intends to pay more attention to this area.He is an excellent candidate, but I am not sure we should not wait a year and allow him to submit to the peer reviewed literature.I will speak with him again, nand perhaps we can hold his submission pending this discussion.Thanks Michael.Steve

Steve Arshinoff MD FRCSC2115 Finch Ave. W #316, Toronto, ON, Canada M3N 2V6Tel: 416 745-6969 Fax: 416 745-6724Email: ifix2is@gmail.com

On Sep 30, 2015, at 4:47 PM, Michael Knorz <knorz@eyes.de> wrote:

Hi Steve,

will you send me a recommendation, too? Otherwise I cannot start the procedure as you know.

Many thanks!

Michael

Prof.&Dr.&Michael&C.&Knorz3&Execu7ve&Director&3&Interna7onal&Intraocular&Implant&Club&(IIIC)London,&UKE3mail:&knorz@eyes.deInternet:&www.iiiclub.org

Execu7ve&Director´s&address:Michael&C.&KnorzFreeVis&LASIK&ZentrumTheodor&Kutzer&Ufer&13368167&MannheimGermanyPhone&+49&151&1577&5321Fax&+49&621&383&1984E3mail:&knorz@eyes.de

Anfang der weitergeleiteten Nachricht:

Von: "Richard L. Lindstrom, MD" <rllindstrom@mneye.com>Betreff: FW: CV Work

Von: Vance Thompson vance.thompson@vancethompsonvision.comBetreff: IIIOC Letter of Intent and Updated CVDatum: 9. Mai 2016 um 08:08

An: Michael Knorz Knorz@eyes.de

Dear Michael, Here is my letter of intent for accepting the nomination to the International Intra-Ocular Implant Club. I am very honored to be nominatedand I would be very honored to be a part of this prestigious society. I have worked hard to update my curriculum vitae and have attachedthe updated version. Thank you so much for considering me. Please let me know if there is anything else I can do. With great respect,Vance

Vance Thompson, MD

3101 West 57th Street

Sioux Falls, SD 57108M: 605-359-4070

Curriculum Vitae.doc

VanceThompson,MD VanceThompson,MD,graduatedfromGregoryHighSchoolinGregory,South Dakota, and subsequently went on to complete his education at theUniversityofSouthDakota(BS-Chemistry),UniversityofSouthDakotaSchoolof Medicine (MD), Avera McKennan Hospital in Sioux Falls, South Dakota(Internship), University of Missouri – Columbia (Ophthalmology Residency),andHunkeler EyeClinic (Refractive Surgery FellowshipwithDaniel S.Durrie,MD). Dr. Thompson has been practicing refractive, corneal and cataractsurgery in Sioux Falls, South Dakota since 1991 and is a Professor ofOphthalmologyattheUniversityofSouthDakotaSanfordSchoolofMedicine. Dr.Thompsonhasbeenprimaryinvestigatorinover50FDA-monitoredclinicaltrialsstudyinglaser(excimer,holmium,andfemtosecond)andimplant(pseudophakic,phakic,andcornealinlay)visioncorrectionsince1990.HewastheMedicalMonitorofthefirstFDAapprovedophthalmicuseofanexcimerlaser in the United States. He has also been the Medical Monitor of otherstudies and most recently was the co-monitor of Avedro’s corneal collagencrosslinkingtrialwhichwasrecentlyFDAapproved. Dr.Thompsonhasnumerouspublications,includingbeingaco-editorofthe textbook Refractive Surgery and lectures and teaches throughout theworldonrefractivesurgery. Dr.ThompsonhasnumerouscommunityinterestswhichincludeservingontheBoardsoftheUniversityofSiouxFalls,SanfordHealthFoundation,theSouthDakotaSymphony,DakotaCare,USBank,UniversityofSouthDakota,USBank, a presidential appointment to thePresident’sAdvisoryCouncil for thePerformingArtsinWashington,DCfor8yearsduringtheBushadministration,andmore.

CURRICULUMVITAEVANCEM.THOMPSON,M.D.

Birthday:December18,1959 MaritalStatus:MarriedChildren:Three

Clinical/SurgicalPracticeVanceThompsonVision3101West57thStreet SiouxFalls,SD57108

EducationandTraining

Undergraduate8/78-5/82UniversityofSouthDakota,Vermillion,SDBS/1982ChemistryGraduate8/82-5/86UniversityofSouthDakota,Vermillion,SDMD/1986MedicinePost-Graduate7/86-6/87McKennanHospital,SiouxFalls,SD RotatingInternship7/87-6/90UniversityofMissouri,Columbia,MO OphthalmologyResidency7/90-7/91HunkelerEyeClinic RefractiveandCataract SurgeryFellowship

CertificationandLicensure

CertifiedAmericanBoardofOphthalmology

MembershipsinProfessionalandScientificSocietiesAmericanMedicalAssociation AmericanAcademyofOphthalmology/InternationalSocietyofRefractiveKeratoplastyAmericanSocietyofCataractandRefractiveSurgeryAmericanEuropeanCongressofOphthalmicSurgery

FDA Monitored Clinical Trials

1. Phototherapeutic Keratectomy Phase I a. Sponsor: Summit Technology b. My Role: Sub Investigator

2. Phototherapeutic Keratectomy Phase II a. Sponsor: Summit Technology b. My Role: Sub Investigator

3. Photorefractive Keratectomy Phase II Partially Sighted Eyes

a. Sponsor: Summit Technology b. My Role: Sub Investigator

4. Photorefractive Keratectomy Phase III Normally Sighted Eyes

a. Sponsor: Summit Technology b. My Role: Sub Investigator

5. Phototherapeutic Keratectomy Phase III a. Sponsor: Summit Technology b. My Role: Medical Monitor and Principle Investigator

6. Therapeutic Refractive Subset PRK- previous Corneal Refractive Surgery

a. Sponsor: Summit Technology b. My Role: Principle Investigator

7. Myopia/astigmatism PRK. Erodible Mask Phase II A a. Sponsor: Summit Technology b. My Role: Principle Investigator

8. Myopia/astigmatism PRK. Erodible Mask Phase II B a. Sponsor: Summit Technology b. My Role: Principle Investigator

9. Holmium Astigmatism Phase I a. Sponsor: Summit Technology b. My Role: Medical Monitor and Principle Investigator

10. Holmium Astigmatism Phase II a. Sponsor: Summit Technology b. My Role: Medical Monitor and Principle Investigator

11. Holmium Hyperopic Phase III a. Sponsor: Summit Technology b. My Role: Medical Monitor and Principle Investigator

12. LASIK for High Myopia a. Sponsor: Summit Technology b. My Role: Principle Investigator

13. Hyperopic Photorefractive Keratectomy with Emphasis Erodible Mask IDE

a. Sponsor: Summit Technology b. My Role: Principle Investigator

14. Hyperopia LASIK with Astigmatism a. Sponsor: Summit Technology b. My Role: Principle Investigator

15. CRS LASIK for Surgical Treatment of Myopia a. Sponsor: CRS and Summit Technology b. My Role: Principle Investigator

16. CRS LASIK for Hyperopia Expansion to Sub-study D a. Sponsor: CRS and Summit Technology (ask Guy) b. My Role: Principle Investigator

17. CRS LASIK for Hyperopia Astigmatism Substudy E a. Sponsor: CRS and Summit Technology b. My Role: Principle Investigator

18. CRS Study I Myopia Surgical Treatment a. Sponsor: CRS and Summit Technology b. My Role: Principle Investigator

19. KETO 102-8344 Ketorlac Tromethamine Ophthalmic solution (Acular) with Subjects Undergoing

Photorefractive Keratectomy with the Exci Med UV200LA Omni Med Excimer Laser.

a. Sponsor: Allergan and Summit Technology b. My Role: Principle Investigator

20. KETO 106-8718 Ketorolec Nonpreserved Ophthalmic Solution in Subjects Undergoing Radial Keratectomy.

a. Sponsor: Allergan b. My Role: Principle Investigator

21. Eye-Fixation Speculum Study 11-94.2 22. IOL Artisan Myopia Lens for Correction of High Myopia

a. Sponsor: AMO b. My Role: Principle Investigator and I testified at the FDA

Ophthalmic devices panel and helped with approval 23. IOL Artisan Hyperopia Lens for Correction of High

Hyperopia a. Sponsor: AMO b. My Role: Principle Investigator

24. Diagnostic Use of the LADAR-Based Eye Tracker for Measurement of Tracker Signal in Refractive Surgery Patients

a. Sponsor: Summit b. My Role: Principle Investigator

25. A Prospective Multi-center Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay

(ACI) in Presbyopic Subjects a. Sponsor: AcuFocus b. My Role: Principle Investigator

26. Phase III Clinical Study of the Alcon Acrysof Angle- Supported Phakic IOL- Protocol C-05-57

27. Clinical Evaluation of a Modified Light Transmission Tecnis Acrylic Intraocular Lens Phase 3 - Protocol

BBLK-102-PRSM. a. Sponsor: AMO b. My Role: Principle Investigator

28. Clinical Evaluation of the Safety and Effectiveness of the Veriflex Anterior Chamber Phakic IOL for

Correction of Myopia-Protocol VFLX-102-6820. a. Sponsor: AMO b. My Role: Principle Investigator

29. ForSight Vision 3 Observation Study to Assess Vision And Pain Post PRK and LASIK to establish

baseline for subsequent shield to aid in healing and pain study control

a. Sponsor: ForSight Labs b. My Role: Principle Investigator

30. Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain - Protocol CS

004 a. Sponsor: ForSight Labs b. My Role: Principle Investigator

31. Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% for Prevention and Treatment of

Ocular Inflammation and Pain after Cataract Surgery Protocol C-09-055

a. Sponsor: Alcon b. My Role: Principle Investigator

32. Clinical Evaluation of Nepafenac Ophthalmic Suspension, 0.3% Compared to Nepafenac (TWO)

Ophthalmic Suspension 0.1% and Vehicle for Prevention and Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery - Protocol C-11-

003 a. Sponsor: Alcon b. My Role: Principle Investigator

33. Long Term Safety Follow-up for Subjects Previously Implanted with the AcrySof® CACHET® Phakic Lens in

Clinical Studies C-02-23, C-02-40, C-03-21 and C-05-57- Protocol C-09-043

a. Sponsor: Alcon b. My Role: Principle Investigator

34. Post Approval Study of the AcrySof® IQ Toric High Cylinder Power IOL Models SN6AT6-SN6AT9- Protocol

C-11-020 a. Sponsor: Alcon b. My Role: Principle Investigator

35. Evaluation of the LenSx Laser System for Performing Anterior Capsulotomy, Phacofragmentation, and

Corneal Arc Cuts/Incisions in Patients Undergoing Cataract Surgery for Removal of the Crystalline Lens Protocol CPT-002m

a. Sponsor: Alcon b. My Role: Principle Investigator

36. Evaluation of a Modified Disposable Contact Lens Patient Interface for the LenSx Laser in Cataract and

Corneal Surgery-Protocol CPT-006m a. Sponsor: Alcon b. My Role: Principle Investigator

37. A Prospective Randomized Controlled Multi-Center Clinical Study to Evaluation the Safety and

Effectiveness of the Light Adjustable Lens (LAL) in Subjects with Pre- Existing Corneal Astigmatism- Protocol CSP-002-03

a. Sponsor: Calhoun Vision b. My Role: Principle Investigator

38. Patient-Reported Outcomes with LASIK 2 -Protocol PROWL-2

a. Sponsor: United States Food and Drug Administration b. My Role: Principle Investigator

39. A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL

System with VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes with

Keratoconus-Protocol KXL-001 a. Sponsor: Avedro b. My Role: Principle Investigator and co-Medical Monitor

40. A Multi-Center, Randomized, Controlled Evaluation of

the Safety and Efficacy of LASIK With Cross-linking Performed with the KXL System and Photrexa ZD (Riboflavin Ophthalmic Solution) Compared to LASIK Alone for Hyperopia and Hyperopic Astigmatism Phase 1,2 Protocol KXL-004

a. Sponsor: Avedro b. My Role: Principle Investigator

41. A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of the KXL System with VibeX

(Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes with Keratoconus or Corneal Ectasia After Refractive Surgery Phase 3 Protocol ACOS-KXL-001

a. Sponsor: Avedro b. My Role: Principle Investigator and co-Medical Monitor

42. Evaluation of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront- Optimized LASIK with

Contralateral NexisVision Shield or Bandage Contact Lens or Standard LASIK Without a Shield or Bandage Contact Lens- Protocol CNVS-VR-002

a. Sponsor: ForSight Labs b. My Role: Principle Investigator

43. Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia

Phase 1 - Protocol VISUMAX-2012-1 a. Sponsor: Zeiss b. My Role: Principle Investigator

44. A Continuation Study to Monitor the Long Term Safety of the AcuFocus ACI 7000PDT Patients Completing

Protocols ACU-P08-020/020A Protocol ACU-P12-020C a. Sponsor: AcuFocus b. My Role: Principle Investigator

45. Prospective Safety and Effectiveness Study of PRK for

Myopia With or Without Astigmatism Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System-

Protocol C-10-084 a. Sponsor: Alcon b. My Role: Principle Investigator

46. A Non-Randomized, Open-Label Study to Evaluate the

Safety and Effectiveness of Nasal Stimulation Therapy for Tear Production with the Oculeve Intranasal Lacrimal TENS Unit Protocol OCUN-006.

a. Sponsor: Oculeve b. My Role: Principle Investigator

47. Use of the Visumax Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia With or

Without Astigmatism Protocol VISUMAX -2014-1. a. Sponsor: Zeiss b. My Role: Principle Investigator

48. A Multi-Center Clinical Assessment of the Lensar Laser

System of Fragmentation Pattern Groups and Biometry Analysis Phase 4 Protocol 52-00077-PRO.

a. Sponsor: LensAr b. My Role: Principle Investigator

49. Surgeon Evaluation of the Optiwave Refractive Analysis

System with VerifEye+ (ORA System with VerifEye+) Protocol WA-14-005.

a. Sponsor: Wavetec/Alcon b. My Role: Principle Investigator

50. A Prospective, Global, Multi-Center Study to Evaluate Longitudinal Flap Accuracy on

Subjects Undergoing Myopic Refractive Surgery Using the WaveLight Refractive Suite Protocol A01354.

a. Sponsor: Alcon b. My Role: Principle Investigator

51. Crystalens Trulign a. Sponsor: Bausch and Lomb b. My Role: Principle Investigator

52. AMO Toric a. Sponsor: Abbott b. My Role: Principle Investigator

Significant milestones in my research and technology development career:

1. Being a sub-investigator under my fellowship director Dan Durrie in 1990 and being integrally involved in the partially sighted eye study of PRK (the feasibility trial for the ultimate PRK study in the US) was a significant start to my research career. I worked hard to help this trial be a success. That lead to research opportunity #2.

2. Being asked to be an investigator in my home state of South Dakota in the PRK FDA monitored trials in the United States was a significant milestone in my career. It marked the beginning of my research career here in my home state. This lead to research opportunity #3.

3. I was both a principle investigator or PTK and also the Medical Monitor of the Summit Technology U. S. PTK clinical trial. I was part of the testifying team to help get this technology approved. I was honored to help shepherd it this as the Medical Monitor and it was exciting to lead the first FDA approved ophthalmic

use of an excimer laser in the United States. This lead to research opportunity #4.

4. When I was asked to come to New Orleans for an investigators meeting to learn about Excimer Laser MKM (the technique of taking a 300 micron cap off the cornea and lasering the back and then suturing it back on…in the Summit trials this was performed by Steve Brint, MD and Steve Slade, MD) this was a milestone for me. This was the feasibility trial for laser assisted in-situ keratomileusis (LASIK) and allowed me to be in the first group of 7 to perform hinged flap classic LASIK in the United States. We did not fully realize how much this procedure was going to revolutionize eye care in our world.

5. I was one of three investigators in the beginning of the development of the Hansatome along with Steve Slade and Richard Lindstrom. This project was a Chiron project of which Andy Corley was the lead on. This was a very exciting project for me to be a part of. For example, our first flaps were huge (corneoscleral), often 14 mm and we had to advise and help in the optimization of this exciting technology. It was the beginning of a career influenced heavily by Andy Corley.

6. When I was first asked to be a phakic IOL investigator in the Artisan/Verisyse US trial I declined. It was George Waring, III who contacted me and complimented my hard work in the PRK and LASIK FDA monitored trials and asked that I take a closer look at this procedure. I then traveled to Groningen the Netherlands with a mentor I have looked up to my whole career, Richard Lindstrom, MD; both of us were desiring to learn more from the respected Jan Worst, MD and be potential investigators. This was a very important trip for me. I ended up being the largest enroller of patients in Artisan Intraocular clinical trial in the United States and participated as a presenting researcher in the FDA hearing trials in Washington, DC to get this exciting technology FDA approved.

7. I have been on many Medical Advisory Boards over the years but one of them I was the most proud of was the Intralase MAB. When I took delivery of the 5th Intralase device in the world in the fall of 2001 there was no such thing as pocket software. We

had to develop techniques to deal with the meniscus (applanation) in a way to maximize OBL evacuation to the limbus. It was an honor to be an early user of this game changing technology and an honor to be involved in the beginning group of surgeons to optimize it.

8. I was an investigator in the first modern day corneal inlay study in the United States, the AcuFocus KAMRA device. During every phase of the AcuFocus study I was either the largest, or second largest, enroller. I worked hard to help with the optimization of the corneal inlay techniques and was asked to presenting researcher in the FDA hearings in Washington DC that lead to FDA approval.

9. Being asked to be a lead principle investigator in the Calhoun Light Adjustable Lens clinical trials in our country was one of the most exciting opportunities I have had.

10. Being asked to be a SMILE investigator in our country in combination with having been a PRK and LASIK investigator in their beginning trials put me in the unique position of having been involved in the United States beginning of all three of these important procedures in laser corneal refractive surgery in our country.

11. I was a Medical Monitor and lead investigator of the first FDA approved use of crosslinking in the United States…the Avedro technology. I also co-hold two patents with their technology.

12. I have been integrally involved in the development of the Zepto procedure to perform a capsulotomy with a soft collapsible tip and a circular nitinol cutting element. I lead the first study (results published in Ophthalmology) proving this to be the capsulotomy with the strongest resistance to edge tears compared to manual circular tear and femtosecond capsulotomies.

Patents

1. Patent 9044308 B2 Systems and methods for reshaping an eye

feature for crosslinking as a way to change corneal shape for correcting refractive error or zonal treatments

Co-inventors: David Muller, Vance Thompson 2. Patent US 20130238015 A1 Intraocular pressure

modification The assemblies and methods can be used to treat, inhibit, or prevent ocular conditions such as glaucoma, high intraocular pressure, optic disc edema, idiopathic intracranial hypertension, zero-gravity induced papilledema, and other optic pressure related conditions. An assembly can include a goggle including at least one cavity, a pump in fluid communication with the at least one cavity, and a control mechanism. Inventors: John Berdahl, Richard Cornelius, Vance Thompson

3. Patent 20160000885 - Methods for stabilizing corneal tissue Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus.... Inventors: Vance Thompson, Bruce Dewoolfson, Dale Devore

4. Patent - 20160000317 - System for measuring visual fixation disparity There is disclosed herein a system for measuring visual fixation disparity comprising a display apparatus for presenting stereoscopic visual content to a patient. A sensing apparatus tracks eye movement of the patient. A controller controls the display apparatus to stereoscopically display a central image target alternately. Inventors: Jeffrey P. Krall, Vance Thompson, John Merril Davis, (Eyebrain Medical, Inc.)

5. Patent - 20150049301 - Methods and lenses for alleviating asthenopia The invention provides methods and lenses for reducing

asthenopia related symptoms associated with proprioceptive disparity. In certain aspects, lenses of the invention include a distance portion and a near portion, and a progressive increase in minus power from the distance portion to the near portion. Additionally, lenses of the invention... Inventors: Jeffrey P. Krall, Vance Thompson (Eyebrain Medical, Inc.)

6. Patent - 20130045926 - Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema Methods of stabilizing and organizing collagen fibrils in extracellular matrix of retinal tissues, particularly Bruch's membranes, and stabilizing retinal pigment epithelial layers lining Bruch's membrane are disclosed. The stabilization and organization may be effected by treating retinal tissues with a protein that crosslinks and organizes collagen fibrils, such as decorin.... Inventors: Dale P. Devore, Bruce H. Dewoolfson, Vance Thompson

7. Patent - 20120303008 - Systems and methods for reshaping an eye feature Systems and methods include a cutting instrument that creates incisions in selected areas of the cornea; an eye therapy system that applies reshaping forces to the cornea; and a controller that determines the selected areas of the cornea for the incisions and the reshaping forces from the eye therapy system,... Inventors: David Muller, Vance Thompson (Avedro, Inc.)

8. Patent - 20090187178 - System and method for positioning an eye therapy device A system for aligning an eye therapy instrument over a selected area or feature of an eye provides an attachment element that is removably attached to a surface of an eye. A receiving element is coupled to the attachment element and movable relative to the attachment element. The receiving element... Inventors: David Muller, Vance Thompson

9. Patent - 20090105127 - Methods for stabilizing corneal tissue. Methods of stabilizing collagen fibrils in a cornea are disclosed. The stabilization may be effected by treating the cornea with a protein that crosslinks collagen fibrils, such as decorin. The stablization methods include treatment of corneas before, during, or after a surgical procedure, treatment of keratectasia, and treatment of keratoconus.... Inventors: Vance Thompson, Bruce Dewoolfson, Dale Devore (Euclid Systems Corporation.)

Publications

1. WuH,ThompsonV,SteinertR,SladeS,HershP,Editors(Textbook),RefractiveSurgery.1sted-Stuttgart,Germany:ThiemeMedicalPublishers.1998.

2. ThompsonV,BerdahlJ,SolanoJ,etal.ComparisonofManual,FemtosecondLaser,andPrecisionPulseCapsulotomyEdgeTearStrengthinPairedHumanCadaverEyes.Ophthalmology.2016Feb;123(2):265-74.

3. ThompsonV.BerdahlJ,TendlerAEvaluatingFemtosecondLaserTechnologyforYourPractice.In:SladeS,editor.LaserRefractiveCataractSurgery.1sted-Wayne(PA):BrynMawrCommunicationsLLC.

4. ThompsonV.LenSxLaserSystem:ClinicalExperience.In:FemtosecondCataractSurgery:APrimer.1sted-Thorofare(NJ):SlackIncorporated.

5. ThompsonV.2004PostoperativeCareforPhakicIntraocularLenses.In:HardtenD,LindstromL,DavisE,editors.PhakicIntraocularLenses:PrinciplesandPractice.1sted-Thorofare(NJ):SlackIncorporated.

6. StultingR,JohnM,MaloneyR,AssilK,ArrowsmithP,ThompsonV;U.S.VerisyseStudyGroup.Three-yearresultsofArtisan/Verisysephakicintraocularlensimplantation.ResultsoftheUnitedStatesFoodAndDrugAdministrationclinicaltrial.Ophthalmology.2008Mar;115(3):464-472.

7. BrintSF,CheethamJK,DeGryseR,AbelML,ThompsonVM,RosenthalA.Efficacyandsafetyofnonpreservedketorolacophthalmicsolutioninpostoperativeocularpainfollowingradialkeratotomy.JCataractRefractSurg.1999,25:41-9.

8. HershPS,BrintSF,MaloneyRK,DurrieDS,GordonM,MichelsonMA,ThompsonVM,BerkeleyRB,ScheinOD,SteinertRF.Photorefractivekeratectomyversuslaserinsitukeratomileusisformoderatetohighmyopia.Arandomizedprospectivestudy.Ophthalmology.1998,105,1512-22,discussion1522-3.

9. ThompsonV.Refractivesurgeryformyopicandhyperopicastigmatism.

IntOphthalmolClin.1997,37(1):37-49.

10. ThompsonV.Excimerlaserphototherapeutickeratectomy:clinicalandsurgicalaspects.OphthalmicSurgLasers.1995,26(5):461-72.

11. ThompsonV,GordonM.Useoftheexcimerlaserinrefractivesurgery.SeminOphthalmol.1994,9(2):91-6.

12. ThompsonV.Thesurgicalcorrectionofmyopicandhyperopicastigmatism.IntOphthalmolClin.1994Fall;34(4):87-96

13. ThompsonV,SeilerT,SacharoffA,etal.ApplicationoftheHolmiumLaserforRefractiveSurgery.Proc.SPIE2126,OphthalmicTechnologiesIV,28,1994.

14. ThompsonV;DurrieD;HunkelerJ,etal.Applicationoftheholmium:YAGlaserforrefractivesurgery:anupdateofclinicalprogress.Proc.SPIE.1877,OphthalmicTechnologiesIII,52,1993.

15. ThompsonV,DurrieDS,CavanaughTB.Philosophyandtechniqueforexcimerlaserphototherapeutickeratectomy.RefractCornealSurg.1993,9,91-96.

16. ThompsonV,SeilerT,DurrieDS,CavanaughTB.Holmium:YAGlaserthermokeratoplastyforhyperopiaandastigmatism:anoverview.RefractCornealSurg.1993,9,S134-7.

17. WestDR,LischweTD,ThompsonVM,IdeCH.Comparativeefficacyofthebeta-blockersforthepreventionofincreasedintraocularpressureaftercataractextraction.AmJOphthalmol.1988,106,68-73.

18. MaloneyRK,ThompsonV,GhiselliBA,DurrieDS.Aprospectivemulticentertrialofexcimerlaserphototherapeutickeratectomyforcornealvisionloss.AmJOphthalmol.1996;122:149-160.

This is a partial but fairly complete list of publications